Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School
|
|
- Brenda Gibson
- 5 years ago
- Views:
Transcription
1 Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School of Psychology, Fuller Theological Seminary Medical Director, Las Encinas Hospital, Pasadena, CA
2 Financial relationships with commercial interests listed below are not relevant to the CME activity: Takeda Lundbeck Alkermes Allergan
3 1. Explain the link between depression and cardiovascular disease (CVD) and diabetes 2. Recognize signs and symptoms of depression 3. Discuss treatment options for depression in context of comorbid cardiovascular disease and/or diabetes
4 Depression is the leading cause of disability worldwide reported by the World Health Organization 1 Lifetime prevalence rate in the US is 16% 2 Suicide is among the top 10 leading causes of all deaths in the US 3 1. World Health Organization, Fact Sheet, JAMA. 2003; 289 (23): National Vital Statistics Reports, Vol.65, No. 2, Feb 16, 2016, CDC
5 In cardiac patients, MDD prevalence estimated to be as high as 40% 1 Depression is an independent risk factor of CVD 2 Depression doubles the risk of coronary artery disease (CAD) 3 1. Celano, C.M., & Huffman. J.C. Cardiology in Review, 2011;19(3): M. Alvarenga, D. Byrne (eds.), Handbook of Psychocardiology, DOI / _ Srinivasan, K. Indian Journal of Psychiatry. 2011;53(3), 192.
6 Meta analysis of 11 studies found relative risk of developing ischemic heart disease of 1.64 in those with MDD vs healthy controls 1 American Heart Association study found screening positive for depression was associated with a 55% greater risk of cardiac events 2 1. Katon, W.J et al. J of General Internal Medicine, 2004; 19(12): Elderon, L et al (2011). Circulation, Cardiovascular Quality and Outcomes, 2011; 4(5):
7 Depression developed after acute coronary syndrome (ACS) is associated with worse cardiac outcomes 1 MDD after an episode of unstable angina increases the risk of cardiac events during the following year with a 4-fold increase of cardiac death 2 Patients with MDD are at increased risk of cardiac death, particularly within the first 6 months 3 1. Zuidersima M et al. Psychotherapy and Psycho-somatics, 2001;80(4): Lesperance F et al. Archives of Internal Medicine, 2001;160(9): Ziegelstein RC et al. Archives of Internal Medicine, 2000;160(12):
8 Behavioral factors Sympathetic nervous system Platelet function Inflammation
9 The link between depression and diabetes is bi-directional Type 2 DM has an increased risk of depression 1 Depression has a 60% increased risk of Type 2 DM 2 1. Nouwen A et al. Diabetologia 2010: 53: Mezuk B. Eaton WW, Albrecht S, Golden SH. Diabetes Care 2008; 31:
10 Depression is link to prognostic variables including micro and macrovascular complications 1 Even in the context of good glucose control, depression is found to increase all cause mortality 2 1. De Groot M et al. Psychosomatic Medicine 2001;63(4): Sullivan MD et al. Diabetes Care. 2012;35(8):
11 Recommendations for Screening, Referral, and Treatment Conclusions: The opportunity to screen and treat depression in cardiac patients should not be missed, as effective depression treatment may improve health outcomes Patients with positive screening results should be evaluated by a professional qualified in the diagnosis and management of depression Patients with cardiac disease under treatment for depression should be carefully monitored Coordination of care between healthcare providers is essential Lichtman, JH. Circulation 2008;118:
12
13 Depressed Mood Loss of interest or pleasure Diminished ability to think/concentrate or indecisiveness Significant change in weight or appetite Insomnia or hypersomnia Psychomotor agitation or retardation Fatigue or loss of energy Feelings of worthlessness or excessive guilt Suicidal ideation Cognitive Emotional Physical
14 Screening for depression in patients with coronary heart disease. *Meets diagnostic criteria for major depression, has a PHQ-9 score of 10 19, has had no more than 1 or 2 prior episodes of depression, and screens negative for bipolar disorder, suicidality, significant substance abuse, or other major psychiatric problems. Meets the diagnostic criteria for major depression and 1) has a PHQ-9 score 20; or 2) has had 3 or more prior depressive episodes; or 3) screens positive for bipolar disorder, suicidality, significant substance abuse, or other major psychiatric problem. If Yes to Q.9 suicidal, immediately evaluate for acute suicidality. Judith H. Lichtman et al. Circulation. 2008;118: Copyright American Heart Association, Inc. All rights reserved.
15
16
17 Moderate depression and above may need robust antidepressant treatment. Mild depression and below may only require counseling, relaxation and exercise.
18 *Bipolar Disorder Hirschfeld et al found 21% of those taking antidepressants in a primary care clinic screened positive for bipolar disorder Past history of mania Family history of bipolar disorder Past response to antidepressants Age of onset Quality of Depression *Substance Abuse *Assess for suicide risk Hirschfeld et al. J am Board Fam Pract 2005;18:
19 A useful tool to screen for presence of mood disorder
20 Primary Care Companion J Clin Psychiatry 2008;10(2):
21 Response: defined in clinical trials as a 50% decrease from a baseline score on depression scales (e.g. PHQ-9 if baseline score 18 9) Remission: criteria for depression no longer met
22 In community practice, response to PHQ- 9 is a strong predictor of suicide attempt and suicide death over the following 2 years 1 Anxiety as an acute risk factors 2 Protective factors 1. Simon GE et al. J of Clin Psychiatry 2016;77(2): Busch k et al. Psychiatric Annals 2004;34(5):357
23 Acute Phase (6-12 weeks) Achieve Remission Choose initial treatment aimed at inducing major depressive episode remission Assess response and side effects About 4-8 weeks are needed before concluding partial or no response to intervention Continuation Phase (4-9 months) Preserve Remission Continue treatment, monitor for signs of relapse Assess side effects, adherence, and functional status Maintenance Phase Minimize Recurrence Continue for patients at risk (eg. >3 prior MDEs, presence of residual symptoms) Monitor at regular intervals
24 SADHART study 1 ENRICHD study 2 Meta-Review of pharmacological Tx of depression with comorbid DM 3 1. Serebruany VL et al. Circulation, 2003; 108(8): Pizzi, C et al. The American Journal of Cardiology 2011; 107(7): Lancet Diabetes Endocrinol 2015; 3:
25 Depressed patients receiving treatment with an SSRI had a 42% reduction in death or recurrent MI Sertraline and citalopram are the first line antidepressant drug for patients with CVD If patients had responded previously to another antidepressant, resume if not contraindicated
26 Contraindications: Tricyclic antidepressants and monoamine oxidase inhibitors are contraindicated Considerations: Weight gain and metabolic issues with some treatment Dual indications (psychiatric and medical) with duloxetine
27 1950s 1980s 1990s MAOI/ TCAs Miscellaneous SSRIs tranylcypromine phenelzine imipramine nortriptyline bupropion mirtazapine nefazodone trazodone fluoxetine sertraline paroxetine citalopram escitalopram 1990s 2000s SNRIs Antipsychotic Adjunct Other venlafaxine duloxetine desvenlafaxine aripiprazole quetiapine XR olanzapine+ fluoxetine brexpiprazole vilazodone vortioxetine Levomilnacipran ER
28 Optimize treatment to reduce depressive symptoms and improve cardiac prognosis and/or glycemic control Trials which used collaborative care approaches that target improvement of both general medical conditions and comorbid depression have been successful 1 1. Katon WJ et al. N Eng J Med 2010;363:2611
29 Prospective, randomized control trials N~3000 tx-seeking pts instead of volunteers Replicated real-world outpatients co-morbid medical, psychiatric conditions, substance abuse Average of moderately severe depression Ave ~3.3 general medical condition 2/3 at least 1 concurrent axis I psychiatric disorder All started with citalopram Rush et al. Am J Psychiatry 2006;163:
30
31 Level 1 (2876) 32.9 Level 2 (1439) 30.6 Switch (789) 27.0 Augment (650) 35.0 Level 3 (377) 13.6 Switch (235) 10.3 Augment (142) 19.1 Level 4 (109) 14.7 By QIDS-SR 16 <5 at level exit
32 Prozac, Prozac Weekly, Sarafem (approved for PMDD) Usual dose: 20-40mg/day, 60mg for bulimia, OCD Titrate up by 10-20mg q4weeks Best matched for pts with hypersomnia, psychomotor retardation, apathy, & fatigue Most well-studied for bulimia nervosa Long t ½ (2-3 days, 14 days for metabolite) & active metabolite (norfluoxetine) Potent inhibitor of liver enzyme (2D6, 3A4)-many DDIs Common side effects: Activating (insomnia, headache, anxiety) 32
33 Zoloft Dosage: mg/day; titrate up by 50 mg q2weeks (usual dose: mg/day) Approved for OCD in children > 6 y.o. Must be given with food ( bioavailability by ~40%) Often well tolerated Common side effects: Mild S.E.--nausea, diarrhea, insomnia or sedation 33
34 Paxil, Paxil CR Usual Dose: mg/day, titrate up by 10 mg q2weeks Preferred for pts w/ anxiety symptoms (most well studied in this population) No active metabolite Most case reports of 5HT withdrawal (additive w/ anticholinergic rebound) 12/05: increased risk of heart defects when used in 1 st trimester pregnancy (1.5-2% vs. 1%) Common side effects: anticholinergic (constipation, dry mouth, sedation), weight gain, sexual dysfunction 34
35 Citalopram (Celexa ) Dosage: mg/day; titrate up by 10 mg q2weeks Often used in geriatrics population or for those w/ polypharmacy d/t low DDI Inconsistent therapeutic action at lower doses Often need titration to higher doses Common side effects: mild S.E. Very well tolerated. Escitalopram (Lexapro ) Dosage: mg/day Active S-enantiomer 10 mg Lexapro = mg Celexa Fewest drug interactions of the SSRIs 35
36 Wellbutrin, Wellbutrin SR, XL, Zyban Usual dose: 300 mg/day, titrate by 150 mg q 3-7days SR (twice daily): NTE 200 mg/dose, max/day: 400 mg XL (once daily): 450 mg/day max Common side effects: Activating (headache, insomnia, anxiety, agitation) NO sexual dysfunction Should not use in patients with seizure d/o, eating disorders, alcoholics d/t risk of seizure 36
37 Remeron, Remeron SolTab Usual dose: mg/day, titrate by 15 mg q1-2 weeks. Max: 45 mg/day Multiple mechanism enhance efficacy Good especially for thin insomniacs (esp. elderly) Common side effects: sedation (higher at lower doses), appetite, weight gain, triglycerides, dizziness Minimal drug-drug interaction NO sexual dysfunction 37
38 Effexor, Effexor XR Act as a serotonin and norepinephrine reuptake inhibitor (SNRI) Also approved for GAD, SAD & PD Dosage: mg/day Common side effects: nausea, headache, insomnia, blood pressure (dose related effect), sexual dysfunction
39 Cymbalta Acts as a serotonin and norepinephrine reuptake inhibitors (SNRI) FDA approved for MDD, diabetic peripheral neuropathy, & fibromyalgia Dosage: mg/day, neuropathy/ fibromyalgia: mg/d Common side effects: nausea, dry mouth, constipation, sweating, sexual dysfunction
40 Viibryd The first and only SSRI and 5HT1A partial agonist No associated effects on blood pressure, heart rate, or EKG parameters Appears to have benefit with anxiety associated with major depression Dosage range: 10mg-40mg
41 Fetzima Potent and selective SNRI Has shown significant improvement in functional impairment Has been associated with increased heart rate, warnings to monitor prior to and periodically throughout treatment Dosage range: 20mg-120mg
42 Trintellix Multiple pharmacological activity including SERT and 5 serotonin subreceptors (classified MOA by WHO as other ) FDA registration trial with the elderly showing safety and efficacy at 5mg/day An FDA advisory committee has recommended it becomes the first antidepressant with an indication for improvement in cognitive functioning in major depression Dosage range: 5mg-20mg
43 Other biological interventions (TMS,ECT) Cognitive behavioral therapy (CBT) Psychoeducation Cardiac rehabilitation Collaborative Care Programs
44 Depression is a common comorbidity with cardiac disease and diabetes, resulting in worst clinical outcomes Cardiac and diabetic patients should be routinely screened for depression and suicidaility The PHQ-2 and PHQ-9 are established screening tools in the primary care setting Treatment should be monitored with remission as the goal Collaborative treatment is most effective with coordination of care between healthcare providers
45 Screening for depression in patients with coronary heart disease. *Meets diagnostic criteria for major depression, has a PHQ-9 score of 10 19, has had no more than 1 or 2 prior episodes of depression, and screens negative for bipolar disorder, suicidality, significant substance abuse, or other major psychiatric problems. Meets the diagnostic criteria for major depression and 1) has a PHQ-9 score 20; or 2) has had 3 or more prior depressive episodes; or 3) screens positive for bipolar disorder, suicidality, significant substance abuse, or other major psychiatric problem. If Yes to Q.9 suicidal, immediately evaluate for acute suicidality. Judith H. Lichtman et al. Circulation. 2008;118: Copyright American Heart Association, Inc. All rights reserved.
46 Depression is a common and modifiable risk factor for CVD and diabetes Screening and treatment of depression can have significant positive impact and course of these illness
47
Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationDepression & Anxiety in Adolescents
Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationBRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.
BRIEF ANTIDEPRESSANT OVERVIEW Casey Gallimore, Pharm.D., M.S. Antidepressant Medication Classes First Generation Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Second Generation
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationAdult Depression - Clinical Practice Guideline
1 Adult Depression - Clinical Practice Guideline 05/2018 Diagnosis and Screening Diagnostic criteria o Please refer to Attachment A Screening o The United States Preventative Services Task Force (USPSTF)
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationCommon Antidepressant Medications for Adults
(and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationDr.Rahiminejad Roozbeh Hospital TUMS
Dr.Rahiminejad Roozbeh Hospital TUMS Psychiatric disorders, particularly depression, anxiety and eating disorders, are prevalent in diabetes. Mental illness increases risk of diabetes and diabetic complications.
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other BUPROPION HCL WELLBUTRIN, 01653 WELLBUTRIN SR, WELLBUTRIN XL BUPROPION HBR APLENZIN 17050 16996 26198 CITALOPRAM CELEXA 10321 GPID 16344 HYDROBROMIDE DESVENLAFAXINE
More informationRealities of Depression in Primary Care Setting
Realities of Depression in Primary Care Setting Jaroslava Salman, MD Department of Supportive Care Medicine Division of Psychiatry Click to edit Master Presentation Date August 4 th 2018 Disclosure I have
More informationFamily Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University
APPROACH TO DEPRESSION IN PRIMARY CARE Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University DISCLOSURE Speaker/Presenter Disclosure
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationDepression. There are several forms of depression (depressive disorders). Major depressive disorder and dysthymic disorder are the most common.
Depression Depression is a state of low mood and aversion to activity that can affect a person's thoughts, behavior, feelings and sense of well-being. People with depressed mood can feel sad, anxious,
More informationCOMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*
COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* Bupropion (Wellbutrin) Start: IR-100 mg bid X 4d then to 100 mg tid; SR-150
More informationDepression: Identification, Evaluation and Management in Primary Care
Depression: Identification, Evaluation and Management in Primary Care Primary Care Medicine: Update 2010 Rena K. Fox, M.D. Associate Professor of Clinical Medicine University of California, San Francisco
More informationMAJOR DEPRESSION CLINICAL PRACTICE GUIDELINE
MAJOR DEPRESSION CLINICAL PRACTICE GUIDELINE Reviewed and Updated by the Behvioral Health Subcommittee 7/20/2017 Topic Purpose Access Assessment 7/2017 Recommendations SummaCare Health Plan bases its Clinical
More informationFocusing on Depression in the Community. Kelly N. Gable, Pharm.D., BCPP Associate Professor SIUE School of Pharmacy
Focusing on Depression in the Community Kelly N. Gable, Pharm.D., BCPP Associate Professor SIUE School of Pharmacy Disclosure and Conflict of Interest Dr. Gable declares no conflicts of interest, real
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationTreatment of Major Depressive Disorder
Treatment of Major Depressive Disorder Sarah Mullowney, MD PGY3 Psychiatry Resident, University of Utah Paula Gibbs, MD Medical Director of 5 West at UUMC Clerkship Director MS III Psychiatric Rotation
More informationDiabetes and Depression. Roshini Pinto-Powell, MD Stephen Noyes, LICSW, LADC William Gunn, PhD Beverly Bean, RN, C
Diabetes and Depression Roshini Pinto-Powell, MD Stephen Noyes, LICSW, LADC William Gunn, PhD Beverly Bean, RN, C 2008 Learning Objectives State the risk factors for depression Identify the vulnerability
More informationJoel V. Oberstar, M.D. 1
Diagnosis and Treatment of Depressive Disorders in Children and Adolescents Joel V. Oberstar, M.D. CEO & Chief Medical Officer Adjunct Assistant Professor of Psychiatry University of Minnesota Medical
More informationTreatment of Depression in the Primary Care Office
Treatment of Depression in the Primary Care Office Paul E.A. Glaser, MD, PhD Departments of Psychiatry, Pediatrics and Anatomy & Neurobiology University of Kentucky November 5, 2010 Disclosures of Potential
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationPartners in Care Quick Reference Cards
Partners in Care Quick Reference Cards Supported by the Agency for Healthcare Research and Quality MR-1198/8-AHRQ R This project was funded by the Agency for Healthcare Research and Quality (AHRQ), formerly
More informationPharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007
Pharmaceutical Interventions Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007 Outline Overview Overview of initial workup and decisions in elderly depressed individual
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationConsultant Pharmacist Approach to Major Depressive Disorder
Consultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO Objectives What is Depression? Discuss the epidemiology of depression
More informationConsultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO
Consultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO Objectives What is Depression? Discuss the epidemiology of depression
More informationDepression. University of Illinois at Chicago College of Nursing
Depression University of Illinois at Chicago College of Nursing 1 Learning Objectives Upon completion of this session, participants will be better able to: 1. Recognize depression, its symptoms and behaviors
More informationDepression: A Darker Shade of Blue. CareOregon Pharmacy
Depression: A Darker Shade of Blue CareOregon Pharmacy Today s Agenda Welcome and Introduction 8:00 Clinical & In Real Life Aspects 8:05 Break 9:15 Medication Review 9:30 Questions 10:30 Closing 10:55
More informationTreatment-resistant depression in primary care
Treatment-resistant depression in primary care Interprofessional CME, October 2017 Brian J. Mickey, MD, PhD Associate Professor School of Medicine Department of Psychiatry Disclosures Speakers bureau:
More informationIt is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:
Clinical Policy: (Seroquel XR) Reference Number: CP.PMN.64 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationPrepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.
Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Sources: National Institute of Mental Health (NIMH), the National Alliance on Mental Illness (NAMI), and from the American Psychological Association
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationDepression: Identification, Evaluation and Management in Primary Care
Depression: Identification, Evaluation and Management in Primary Care Primary Care Medicine: Update 2012 Rena K. Fox, M.D. Associate Professor of Clinical Medicine University of California, San Francisco
More informationPharmacy Technician Objectives. Pharmacist Objectives. Pre-Test Question 2. Pre-Test Question 1 9/27/2016. Disclosure and Conflict of Interest
Disclosure and Conflict of Interest Focusing on Depression in the Community Kelly N. Gable, Pharm.D., BCPP Associate Professor SIUE School of Pharmacy Dr. Gable declares no conflicts of interest, real
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationDepression major depressive disorder. Some terms: Major Depressive Disorder: Major Depressive Disorder:
Depression major depressive disorder Oldest recognized disorder: melancholia It is a positive and active anguish, a sort of psychical neuralgia wholly unknown to normal life. - William James "I am now
More informationANTI-DEPRESSANT MEDICATIONS
ANTI-DEPRESSANT MEDICATIONS This information is not intended to be a substitute for medical advice. It s purpose is solely informative. If your client or yourself are taking antidepressants, do not change
More informationDisclosure Information
Disclosure Information I have no financial relationships to disclose. I will discuss the off label use of several depression and anxiety medications in pediatric population Pediatric Depression & Anxiety
More informationPractice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association
Practice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association Our clinical advisor adds updated advice on electroconvulsive therapy, transcranial magnetic
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Antidepressant Agents Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Antidepressant Agents Prime Therapeutics will review Prior Authorization requests.
More informationPsychopharmacological Management of Depressive and Anxiety Disorders
Psychopharmacological Management of Depressive and Anxiety Disorders Waseem Ahmed, M.D Medical Director: Population Health and Dallas County Correctional System Email: waseem.ahmed@phhs.org Tel: 214-653-2927
More informationMajor Depressive Disorder
Major Depressive Disorder HEDIS Measures And Clinical Practice Guidelines Jennifer Highley, PMHNP-BC Behavioral Health West Point Healthcare Effectiveness Data and Information Set (HEDIS) Performance measures
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationAre All Older Adults Depressed? Common Mental Health Disorders in Older Adults
Are All Older Adults Depressed? Common Mental Health Disorders in Older Adults Cherie Simpson, PhD, APRN, CNS-BC Myth vs Fact All old people get depressed. Depression in late life is more enduring and
More informationJudges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children
Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17
More informationTREATMENT OF DEPRESSION IN LATE LIFE. Robert Kohn, MD
TREATMENT OF DEPRESSION IN LATE LIFE Robert Kohn, MD WHY TREAT ELDERLY PERSONS Major depression is not a normal part of aging The rates are lower than younger cohorts The prevalence rates are still high
More informationThe Context: Why is this so important to treat?
Depression for PG1s Ian A. Cook, M.D. UCLA Department of Psychiatry Laboratory of Brain, Behavior, and Pharmacology Semel Institute for Neuroscience & Human Behavior DepressionLA.com PsychiatryGuidelines.com
More informationAntidepressants Choosing the Right One
Antidepressants Choosing the Right One Dr Lim Boon Leng Consultant Psychiatrist Dr BL Lim Centre For Psychological Wellness #09-09, Gleneagles Medical Centre, 6 Napier Rd, S258499 www.psywellness.com.sg
More informationAntidepressant Agents Step Therapy and Quantity Limit Program Summary
Antidepressant Agents Step Therapy and Quantity Limit Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-20,26,27,30,32-35,37-39,40,41,43 Drug MDD OCD PD GAD SAD PDD PTSD Bulimia Other Diagnos es Dosing
More informationIlluminating the Black Box: Antidepressants, Youth and Suicide
Illuminating the Black Box: Antidepressants, Youth and Suicide David H. Rubin, M.D. Executive Director, MGH Psychiatry Academy Director, Postgraduate Medical Education Director, Child and Adolescent Psychiatry
More informationDepression: Identification, Evaluation and Management in Primary Care
Depression: Identification, Evaluation and Management in Primary Care Primary Care Update: 2013 I have nothing to disclose Rena K. Fox, M.D. Associate Professor of Clinical Medicine University of California,
More informationThe Latest in Treating Depression and Anxiety in Primary Care
The Latest in Treating Depression and Anxiety in Primary Care Wendy L. Wright MS, ANP-BC, FNP-BC, FAANP, FAAN, FNAP Adult/Family Nurse Practitioner Owner Wright & Associates Family Healthcare @ Amherst
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Trintellix) Reference Number: CP.PMN.65 Effective Date: 05.01.15 Last Review Date: 08.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy
More informationClinical Policy: Vilazodone (Viibryd) Reference Number: CP.PMN.145 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Viibryd) Reference Number: CP.PMN.145 Effective Date: 08.01.12 Last Review Date: 08.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for
More informationAnti-Depressant Medications
Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change
More informationOptimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE
Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic
More informationWhere to from Here? Evidence-Based Strategies for Treatment of Refractory Depression
Where to from Here? Evidence-Based Strategies for Treatment of Refractory Depression Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Major Depression #1 WHO cause of disability
More informationDrugs for Emotional and Mood Disorders Chapter 16
Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,
More information90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR
Pre - PA Allowance 12 years of age or older Quantity Immediate-release Formulation Ultracet 720 dosage units per 90 days OR Ultram 720 dosage units per 90 days Extended-release Formulations Ultram ER 90
More informationDepression: Assessment and Treatment For Older Adults
Tool on Depression: Assessment and Treatment For Older Adults Based on: National Guidelines for Seniors Mental Health: the Assessment and Treatment of Depression Available on line: www.ccsmh.ca www.nicenet.ca
More informationManagement of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors*
Management of SSRI Induced Sexual Dysfunction John J. Miller, M.D. Medical Director, Center for Health and WellBeing Exeter, NH Serotonin Reuptake Inhibitors* fluoxetine clomipramine sertraline paroxetine
More informationResistance is not futile: working with refractory depression and anxiety
Resistance is not futile: working with refractory depression and anxiety Divulgation des conflits d intérêts Conseil consultatif ou comité analogue Essais cliniques ou études Honoraires ou autres revenus
More informationPart 2: Pain and Symptom Management Depression
Guidelines & Protocols Advisory Committee Part 2: Pain and Symptom Management Depression Effective Date: February 22, 2017 Key Recommendations Before diagnosing and treating major depressive disorder,
More informationPsychiatric Medication Guide
Psychiatric Medication Guide F O R : N E O N P R I M A R Y H E A L T H C A R E P R O V I D E R S B Y : M I C H E L L E R O M E R O, D O M A Y, 2 0 1 3 Anti-depressants TCA s & MAOI s (Tricyclic Antidepressants
More informationDepression in the Medically Ill
Mayo School of Continuous Professional Development Psychiatry in Medical Settings February 9 th, 2017 Depression in the Medically Ill David Katzelnick, M.D. Professor of Psychiatry, Mayo Clinic College
More informationWhat s New in Depression in 2016? By: Phyliss Nicole Taylor, MD UF Health Jacksonville Psychiatry
What s New in Depression in 2016? By: Phyliss Nicole Taylor, MD UF Health Jacksonville Psychiatry New Depression Screening Guidelines US Preventive Services Task Force (USPSTF) updated its 2009 recommendations
More informationWellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion)
Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion) Generic name: Bupropion Available strengths: 75 mg, 100 mg immediate-release tablets; 100 mg, 150 mg, 200 mg sustained-release tablets (Wellbutrin-SR);
More informationBELBUCA (buprenorphine buccal film)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Belbuca is indicated for the management of chronic pain severe enough to require daily, aroundthe-clock, long-acting opioid treatment for which alternative
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Antidepressant Agents Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Antidepressant Agents Prime Therapeutics will review Prior Authorization requests.
More information#CHAIR2016. September 16 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
#CHAIR2016 September 16 17, 2016 The Biltmore Hotel Miami, FL Sponsored by Depression in Children and Adolescents Karen Dineen Wagner, MD, PhD University of Texas Medical Branch Galveston, TX Karen Dineen
More informationTreating Depression in Adults
Treating Depression in Adults By Deborah Christensen, Ph.D., M.S.C.P. Depressive Disorders represent a broad and heterogeneous group of commonly diagnosed psychological disorders. The DSM adequately describes
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationMajor Depression and Anxiety in Adolescents and Adults
Major Depression and Anxiety in Adolescents and Adults Miggie Greenberg, M.D. Associate Professor of Psychiatry St. Louis University School of Medicine greenbml@slu.edu *NO DISCLOSURES* OBJECTIVES * Recognize
More informationXartemis XR (oxycodone / acetaminophen extended release)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Xartemis XR is a combination of oxycodone and acetaminophen in a dosage formulation to deliver both immediate pain relief, in less than an hour, and extended-release
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationResident Rotation: Collaborative Care Consultation Psychiatry
Resident Rotation: Collaborative Care Consultation Psychiatry Anna Ratzliff, MD, PhD Ramanpreet Toor, MD James Basinski, MD With contributions from: Jürgen Unützer, MD, MPH, MA Jennifer Sexton, MD, Catherine
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationAnxiety Disorders.
Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationRecognizing Depression and Restoring Mood and Well- Being in the Older Patient
Recognizing Depression and Restoring Mood and Well- Being in the Older Patient Andreea L. Seritan, MD UC Davis Mini Medical School February 22, 2014 Objectives Review late life depression symptoms Review
More informationThe Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?
The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD and Kellie Bunn, PA-C What are functional GI
More informationMajor Depressive Disorder: Diagnosis, Treatment & Impact on Rural Communities
Page 1 Major Depressive Disorder: Diagnosis, Treatment & Impact on Rural Communities Elizabeth Montagnese, M.D. Adult, Child and Adolescent Psychiatrist This program has been supported by an educational
More informationHow to treat depression with medication: Some rules of thumb
How to treat depression with medication: Some rules of thumb R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon. Consultant Psychiatrist Regional
More informationOXYCODONE IR (oxycodone)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Oxycodone hydrochloride, a pure opioid agonist, is used in the treatment of moderate to severe pain (1-2). The precise mechanism of action is unknown; however,
More informationA Basic Approach to Mood and Anxiety Disorders in the Elderly
A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict
More informationComorbid Conditions and Antipsychotic Use in Patients with Depression
Comorbid Conditions and Antipsychotic Use in Patients with Depression Thomas W. Heinrich, MD Professor of Psychiatry and Family Medicine Director, Division of Consultation-Liaison Psychiatry Medical College
More information1 1 Evidence-based pharmacotherapy of major depressive disorder. Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A.
1 1 Evidence-based pharmacotherapy of major depressive disorder Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A. Nierenberg Massachusetts General Hospital and Harvard University, Boston,
More information